Lineage Cell Therapeutics, Inc.
LCTX
$1.61
$0.031.90%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -241.41% | -236.42% | -69.14% | 31.49% | 13.39% |
| Total Depreciation and Amortization | 14.78% | 4.90% | -6.14% | -14.08% | -11.99% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,207.16% | 1,358.82% | 451.74% | -71.09% | 21.17% |
| Change in Net Operating Assets | 53.11% | -3.35% | -174.73% | -50.18% | 18.86% |
| Cash from Operations | 18.07% | 10.45% | -2.47% | 3.95% | 19.16% |
| Capital Expenditure | 7.61% | -67.70% | -84.91% | -19.08% | 16.17% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -642.11% | -1.77% | 168.58% | -99.18% | -103.70% |
| Cash from Investing | -483.06% | -5.98% | 177.35% | -101.18% | -104.97% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -9.26% | -9.43% | -5.77% | -1.85% | 0.00% |
| Issuance of Common Stock | -23.07% | 106.53% | 81.26% | 31.98% | 437.84% |
| Repurchase of Common Stock | -252.17% | 63.96% | 63.96% | 93.24% | 90.25% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -300.00% | -529.65% | -458.05% | -- | -- |
| Cash from Financing | -24.84% | 100.60% | 77.40% | 31.49% | 458.26% |
| Foreign Exchange rate Adjustments | 516.84% | 48.77% | 231.02% | 55.45% | 62.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -148.54% | 443.02% | 394.65% | -84.98% | -56.93% |